key: cord-1028533-0jb05l3u
authors: Sun, Le-Yun; Chen, Cheng; Su, Jianpeng; Li, Jia-Qi; Jiang, Zhihui; Gao, Han; Chigan, Jia-Zhu; Ding, Huan-Huan; Zhai, Le; Yang, Ke-Wu
title: Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals
date: 2021-04-08
journal: Bioorg Chem
DOI: 10.1016/j.bioorg.2021.104889
sha: 6d6df8c483b55ef970a83b18c813db6b277abac6
doc_id: 1028533
cord_uid: 0jb05l3u

The emerging COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised a global catastrophe. To date, there is no specific antiviral drug available to combat this virus, except the vaccine. In this study, the main protease (Mpro) required for SARS-CoV-2 viral replication was expressed and purified. Thirty-six compounds were tested as inhibitors of SARS-CoV-2 Mpro by fluorescence resonance energy transfer (FRET) technique. The half-maximal inhibitory concentration (IC50) values of Ebselen and Ebsulfur analogs were obtained to be in the range of 0.074-0.91 μM. Notably, the molecules containing furane substituent displayed higher inhibition against Mpro, followed by Ebselen 1i (IC50 = 0.074 μM) and Ebsulfur 2k (IC50 = 0.11 μM). The action mechanism of 1i and 2k were characterized by enzyme kinetics, pre-incubation and jump dilution assays, as well as fluorescent labeling experiments, which suggested that both compounds covalently and irreversibly bind to Mpro, while molecular docking suggested that 2k formed an S–S bond with the Cys145 at the enzymatic active site. This study provides two very potent scaffolds Ebsulfur and Ebselen for the development of covalent inhibitors of Mpro to combat COVID-19.

A highly infectious viral disease caused by SARS-CoV-2 became a global epidemic since its outbreak in December 2019 [1] . In February 2020, the World Health Organization (WHO) has elevated its risk of COVID-19 to 'very high' globally [2] . The basic reproduction number (R 0 ) of this viral disease was estimated at the range of 2.24-3.18 [3] , indicating that SARS-CoV-2 has high transmission efficiency. As of December 11, 2020 , there are more than 1,500,000 deaths out of 68,000,000 confirmed cases in 220 countries (https://www.who.int/emergencies/diseases/novel-coronavirus-2019). SARS-CoV-2, as the name indicates, is close to SARS-CoV and MERS-CoV, which belong to the beta lineage of the coronavirus [4] . The genome of SARS-CoV-2 contains the largest single-stranded, positive-sense RNA with approximately 30,000 nucleotides. The viral genome consists of 14 open reading frames, which mainly encode several non-structural, structural, and accessory proteins [5] . The low toxic compounds that target any of these viral proteins may be the potential antiviral drug candidates [6] .

Based on the evidence from the clinical studies, the Remdesivir has been used to treat COVID-19, but the therapeutic effect remains very limited [7] . As a consequence, safe and effective therapy is urgently needed.

The main protease (M pro ), also called the chymotrypsin-like protease (3CL pro ), is considered one of the most characteristic drug targets in coronavirus. It is composed of three domains that could form a functional dimer. Residues 8-101 (Domains I) and

residues 102-184 (Domain II) are the catalytic domains. Residues 201-303 (Domain III) are responsible for the enzyme dimerization [8, 9] . The M pro , a cysteine protease with an unconventional Cys catalytic residue, plays an essential role in coronavirus replication and transcription by digesting the polyproteins at more than 11 conserved sites. However, unlike other Cys (or Ser) hydrolases, it has a catalytic Cys-His (Cys145 and His41) dyad in the gap rather than a canonical Cys (Ser)-His-Asp (Glu) triad [10] .

In addition, it is known to have recognition sequence of Leu-Gln (Ser, Ala, Gly) at the P1 site (↓ marks the cleavage site). Notably, the Gln residue is virtually always required in the P1 position [8, 11] . However, no homolog of M pro exists in humans, therefore, M pro is the ideal target for antiviral therapy [12] .

To date, several approaches including high-throughput screening, virtual screening, drug design, and drug repurposing have been used to develop the potential inhibitors of SARS-CoV-2. Based on the fact that similar therapeutic regimens are commonly used for viral diseases associated with SARS-CoV-2, drug repurposing is now attracting attention with the advantages of lower cost and greater safety, especially medicines where pre-clinical safety studies have been conducted [13] . Several drugs, such as azithromycin [14] , lopinavir/ritonavir [15] , remdesivir [16] , and favipiravir [17] , have been currently suggested as antiviral drug candidates. However, due to the limited therapeutic efficacy of these drugs and the toxic side effects at high doses, only remdesivir has so far been approved by the FDA.

Given currently urgent need, the high-throughput and virtual screening may become a rapid and effective means for drug discovery. An in-silico attempt has been made to perform a large-scale virtual screening of enzyme inhibitors [18] , these enzyme include M pro [19] [20] [21] , taste receptors (TR) [22] , cyclin-dependent kinases (CDKs) [23] , dual-specificity tyrosine-phosphorylation regulated kinase-1A (DYRK1A) [24] , and checkpoint kinase 1 (CHK1) [25] . To develop anti-viral medicines with clinical potential, a large amount of M pro inhibitors were reported, such as aldehyde peptidomimetics [26] , α-ketoamide [27] , benzotriazole [28] , and decahydroisoquinoline [29] , GC-376 analogs [30] , aldehydes [31] . Recently, Brul et al reported that the Ebselen and its analogs to be potent covalent inhibitors of papain-like protease [32] . In this study, a fluorescence resonance energy transfer (FRET)-based enzymatic assay was employed to screen the inhibitors of M pro , and the Ebselen and Ebsulfur derivatives were found to be very highly promising scaffolds for targeting the enzyme. This study provides additional insights to Ebselen and Ebsulfur derivatives.

The action mechanism was also characterized by enzymatic kinetics and fluorescent labeling. The interaction of M pro and the identified inhibitor was further investigated by molecular docking studies.

The M pro gene was inserted into the PGEX-6P-1 vector and expressed in BL21 E.

coli. The recombinant M pro with native C and N termini was purified through Ni-NTA and HiTrap Q FF column (Fig. 1a) . The enzymatic activity was assayed by timedependent kinetics using Mca-AVLQ/SGFRK(Dnp)K as fluorescent substrate [33] . 

The fluorescence resonance energy transfer (FRET) experiments were employed to identify the potential inhibitors of M pro [35] . Thirty-six compounds (Table 1) were screened, including Ebselen, Ebsulfur derivatives and compounds 3-11. These compounds were synthesized in our lab and characterized by NMR and mass spectrometry and evaluated to be the effective Metallo-β-lactamase inhibitors [36] [37] [38] [39] [40] [41] [42] .

The compounds 3-11 have been identified to inhibit NDM-1 (cysteine protease). M pro is also a cysteine protease, so we were interested in verifying whether these compounds have an inhibitory effect on M pro . The percentage inhibition of M pro with compounds is shown in Fig. 2 , which was calculated from enzyme activity without inhibitor (100%) minus residual activity with inhibitor. The Ebselen 1j has been reported to be the inhibitor of M pro with an IC 50 value of 0.67 μM [34] . In this work, we used 50 µM 1j

as the positive control and 0.5% DMSO was used as the negative control in the absence of inhibitor. Encouragingly, it is clearly observed that both Ebselen and Ebsulfur exhibited more than 95% inhibition against M pro , but compounds 3-11 had less than 40%

inhibition. In this case, the following work would focus on the studies of Ebselen and Ebsulfur derivatives. 

Based on the encouraging results of the preliminary screening, the half-maximal inhibitory concentrations (IC 50 ) of all Ebselen and Ebsulfur derivatives against M pro were determined in the assay buffer using Mca-AVLQSGFRK(Dnp)K as substrate [43] .

The concentrations of substrate and enzyme were 20 and 0.2 μM, respectively, and the concentration of inhibitor was varied in the range of 0 and 2 μM.

The collected IC 50 data (Table 2) shown that all of these compounds had excellent inhibitory efficacy against M pro , exhibiting IC 50 value in the range of 0.074-0.91 μM.

The inhibitors 1i and 2k were also found to be the most potent inhibitors with IC 50 values of 0.074 and 0.11 μM, respectively. It should be noted that all these Ebselen and Ebsulfur derivatives tested had better inhibitory efficacy than the Ebselen molecule recently reported on M pro (IC 50 =0.67 μM), except 2b-c and 2p, the molecule inhibited SARS-CoV-2 replication with an EC 50 value of 4.67 μM [34] . Clearly, both Ebselen and Ebsulfur are highly promising scaffolds for the development of antiviral reagents. 

To further identify the inhibition mode of the Ebselen and Ebsulfur against M pro , the enzyme kinetic parameters were determined. The concentrations of the inhibitors 1i and 2k were varied between 0 and 1 μM, and the FRET substrate concentration was 20 µM.

After proteolysis proceeded for about 16 min, it can be observed that a large amount of substrate was consumed (Fig. 3 , upper column). As shown in Fig. 3 middle column, it is observed that the both inhibitors exhibited a concentration-and time-dependent inhibition pattern against M pro , and the kinetic progression curves for the first 250 s showed a biphasic character, indicating the rate of inactivation follows pseudo-firstorder rate kinetics, which implied that 1i and 2k covalently inhibit M pro [34] . The observed first-order inhibition rate constant (K obs ) were fitted against inhibitor concentration by nonlinear regression to determine the inactivation kinetic parameters Furthermore, a jump dilution assay was performed to evaluate the reversibility of 1i and 2k binding to the M pro [44] . The recombinant M pro was incubated with a high concentration of inhibitors (equivalent to 30×IC 50 ) so that the inhibitor could fully occupy enzymatic active sites, and the resulting mixtures were diluted 100-fold with the fluorogenic substrate solution, it is clear to be observed that neither 1i nor 2k had significant activity recovery (Fig. 4b) , implying that both compounds irreversibly inhibited the target enzyme. 

A fluorescent inhibitor Ebs-R was employed to further investigate the covalent binding of Ebsulfur to M pro by SDS-PAGE [45] . The purified M pro sample was incubated with Ebs-R in 10 mM Tris, pH 6.8, at 25 °C for 1 h, and then the gel was irradiated with UV light at 365 nm to visualize the labeled proteins. The scheme of M pro labeling with Ebs-R is shown in Fig. 5 . A red protein band of approximately 33 kDa was observed, which was confirmed by Coomassie Brilliant Blue (CBB) staining experiments to be consistent with M pro (Fig. 5b, lane 3) . In contrast, no red protein band was observed when M pro was treated with rhodamine B (Fig. 5b, lane 4) , indicating that rhodamine B could not label M pro , suggesting that the Ebsulfur is capable of covalently binding to the active site of M pro and thus exhibit potent inhibitory activity. 

To investigate the effect of DTT on M pro inhibition by Ebselen and Ebsulfur, the enzymatic activity assays with and without DTT (4 mM) were performed. The concentrations of M pro and substrate were 0.2 and 20 μM, respectively. As shown in Fig. 6a , it was found that compounds exhibited strong inhibition on M pro in the absence of DTT, and the results are generally consistent with previous conclusion [46] .

However, in the presence of DTT (4 mM), both compounds did not exhibit a potent inhibitory effect on M pro .

Also, we performed dose-dependent inhibition of M pro in the absence and presence of DTT. As shown in Fig. 6b , in the absence of DTT, the residual activity of M pro decreased with the increase of inhibitor concentration from 0 to 10 μM. However, in the presence of DTT, 1i and 2k were unable to effectively inhibit the enzymatic activity, suggesting that inhibition of the Ebselen and Ebsulfur on M pro was abolished probably due to that DTT disrupted the binding of inhibitors to enzyme, this case is similar to that previously reported [46, 47] . These assays indicate that both Ebselen and Ebsulfur are promiscuous cysteine protease inhibitors.

In addition, Ebselen has been reported to have potent antiviral activity against SARS-CoV-2 [34] . So, it is reasonable to believe that the Ebselen and Ebsulfur derivatives also have cellular antiviral activity, although the antiviral activity may not have a direct correlation with the in vitro enzymatic inhibition against M pro in the absence of DTT. 

According to the reported crystal structure (PDB ID: 6LU7), the three-dimensional structure of M pro was employed to simulate the binding mode of the most effective Ebsulfur 2k [34] . It has been reported that Cys145 is a key residue in the active site of M pro , which makes the residue an attractive target for covalent bonding [48, 49] . The conformation shown in Fig. 7 

The 

Ebselen 1i and Ebsulfur 2k with effective inhibition were identified in the preliminary inhibitory experiments, and its kinetic parameters were determined as previously described [50] . (2)

Where [I] is inhibitor concentration; K i is the concentration of inactivator at the halfmaximum inactivation rate constant, and k inact is the rate constant of inactivation.

Ebs-R and M pro were firstly dissolved in buffer (10 mM Tris, pH 6.8, 0.5% DMSO) and incubated at room temperature for 2 h. Then an equal volume of the labeled protein was dissolved in 2×SDS gel loading buffer (100 mM Tris, pH 6.8, 20% glycerol, 2.5% SDS) and analyzed by SDS-PAGE. The Gels were observed under 365 nm UV light and finally stained with Coomassie Brilliant Blue.

To further investigate the binding interaction of the inhibitor 2k with M pro , AutoDock 4.2 was used to predict their binding poses [53, 54] . The crystal structure of the M pro complex with the inhibitor N3 (coded 6LU7) was obtained from the Protein Data Bank [34] . Before docking, AutoDockTools were applied to prepare protein by removing all water molecules and then adding hydrogen atoms and charges that modify the PDB files of ligand and receptor. The covalent bond between the enzyme and N3

was also removed. The center coordinates are set according to the center point of N3 (- 

The main protease (M pro ) that the SARS-CoV-2 viral replication employed was expressed and purified, and K m and V max were determined to be 39.1 ± 0.8 µM and 106.3 ± 6 nM/s, respectively. The inhibitory activity of Ebselen and Ebsulfur analogs against M pro was identified using FRET assay with an IC 50 

There are no conflicts to declare.

Clinical features of patients infected with 2019 novel coronavirus in

Comparison of prevalence and associated factors of anxiety and depression among people affected by versus people unaffected by quarantine during the COVID-9 epidemic in Southwestern China

The reproductive number of COVID-19 is higher compared to SARS coronavirus

The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Structural basis of RNA cap modification by SARS-CoV-2

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic

Computational Studies of SARS-CoV-2 3CLpro: Insights from MD Simulations

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

Viral cysteine proteinases

Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur

An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy

Mouse model phenotypes provide information about human drug targets

Impact of azithromycin and/or hydroxychloroquine on hospital mortality in COVID-19

A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19

Compassionate use of remdesivir for patients with severe COVID-19

Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial

Virtual screening of chemical libraries

Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors

Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs

An insilico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2

Elimination of bitter-off taste of stevioside through structure modification and computational interventions

Natural analogues inhibiting selective cyclin-dependent kinase protein isoforms: a computational perspective

Structural based study to identify new potential inhibitors for dual specificity tyrosine-phosphorylationregulated kinase

Discovery and in silico evaluation of aminoarylbenzosuberene molecules as novel checkpoint kinase 1 inhibitor determinants

Peptide aldehyde inhibitors challenge the substrate specificity of the SARScoronavirus main protease

Synthesis of glutamic acid and glutamine peptides possessing a trifluoromethyl ketone group as SARS-CoV 3CL protease inhibitors

Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies

Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors

Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mproand cathepsin L

Structurebased design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2

Production of authentic SARS-CoV M-pro with enhanced activity: Application as a novel tag-cleavage endopeptidase for protein overproduction

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment

Triazolylthioacetamide: A valid scaffold for the development of New Delhi Metallo-β-Lactmase-1 (NDM-1) Inhibitors

Rhodanine as a potent scaffold for the development of broad-spectrum Metallo-βlactamase Inhibitors

Carbamylmethyl mercaptoacetate thioether: a novel scaffold for the development of L1 metallo-β-lactamase Inhibitors

Meta-substituted benzenesulfonamide: A potent scaffold for the development of metallo-betalactamase ImiS inhibitors

Diaryl-substituted azolylthioacetamides: Inhibitor discovery of New Delhi Metallo-beta-Lactamase-1 (NDM-1)

The assemblage of covalent and metal binding dual functional scaffold for cross-class metallo-betalactamases inhibition

Ebsulfur as a potent scaffold for inhibition and labelling of New Delhi metallo-beta-lactamase-1 in vitro and in vivo

Design of wide-spectrum inhibitors targeting coronavirus main proteases

Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis

Covalent protein labeling based on noncatalytic beta-Lactamase and a designed FRET substrate

PX-12, Tideglusib, and Shikonin are nonspecific promiscuous SARS-CoV-2 main protease Inhibitors

Ebselen and diorganylchalcogenides decrease in vitro glutamate uptake by RAT brain slices: Prevention by DTT and GSH

Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates

Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

The behavior and significance of slow-binding enzyme inhibitors

Validating enterovirus D68-2A(pro) as an antiviral drug target and the discovery of telaprevir as a potent D68-2A(pro) Inhibitor

Prediction of novel inhibitors of the main protease (M-pro) of SARS-CoV-2 through consensus docking and drug reposition

Covalent docking using autodock: Two-point attractor and flexible side chain methods

The SARS-CoV-2 main protease is the target to combat COVID-19；

Ebsulfur and Ebselen strongly inhibited the main protease

The Ebsulfur tightly and irreversibly bound the main protease by forming an S-S bond